Literature DB >> 27034182

Prefilled syringes for intravitreal injection reduce preparation time.

Yousif Subhi1, Birgit Kjer, Inger Christine Munch.   

Abstract

INTRODUCTION: The demand for intravitreal therapy has increased dramatically with the introduction of vascular endo-thelial growth factor inhibitors. Improved utilisation of existing resources is crucial to meeting the increased future demand. We investigated time spent preparing intravitreal injection treatment using either prefilled syringes or vials in routine clinical practice.
METHODS: We video-recorded preparations of intravitreal injections (n = 172) for each preparation type (ranibizumab prefilled syringe (n = 56), ranibizumab vial (n = 56) and aflibercept vial (n = 60)) in a multi-centre time and motion study. The preparation times for each step were extracted from videos and the three preparation types were compared.
RESULTS: Prefilled syringes eliminated several steps in the preparation process. Total preparation time was 40.3-45.1 sec. using vials, and the use of prefilled syringes saved 25.5 sec. (95% confidence interval (CI): 23.3-27.6 sec., p < 0.0001). The preparation time when aflibercept vials were used was 3.7 sec. (95% CI: 1.45-5.96 sec., p = 0.0014) longer than when ranibizumab vials were used.
CONCLUSIONS: Prefilled syringes for intravitreal injections reduce preparation time by eliminating preparation steps that both entail a risk of contamination and are subject to variation. The amount of time saved may enable increased utilisation of existing resources and outsourcing to non-ophthalmologists. FUNDING: This study was supported by a grant from Novartis. The funders had no influence on the design of the study, analysis of the data, preparation of the manuscript or the decision to publish. TRIAL REGISTRATION: not relevant.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27034182

Source DB:  PubMed          Journal:  Dan Med J        ISSN: 2245-1919            Impact factor:   1.240


  8 in total

Review 1.  Statement of the German Ophthalmological Society, the German Retina Society, and the Professional Association of Ophthalmologists in Germany on treatment of diabetic macular edema : Dated August 2019.

Authors: 
Journal:  Ophthalmologe       Date:  2021-01       Impact factor: 1.059

2.  Survey of Intravitreal Injection Preferences for the Treatment of Age-Related Macular Degeneration and Macular Edema Among Members of the Turkish Ophthalmological Association.

Authors:  V Levent Karabaş; Ecem Önder Tokuç; Figen Şermet
Journal:  Turk J Ophthalmol       Date:  2022-06-29

Review 3.  Prefilled syringes for intravitreal drug delivery.

Authors:  Thérèse M Sassalos; Yannis M Paulus
Journal:  Clin Ophthalmol       Date:  2019-04-23

Review 4.  Issues with Intravitreal Administration of Anti-VEGF Drugs.

Authors:  Marc Schargus; Andreas Frings
Journal:  Clin Ophthalmol       Date:  2020-03-23

5.  Accuracy of intravitreal injection volume for aflibercept pre-filled syringe and BD Luer-Lok one-milliliter syringe.

Authors:  John-Michael Guest; Brett Malbin; Gary Abrams; Anthony Parendo; Shibandri Das; Chinwenwa Okeagu; Bing X Ross; Ashok Kumar; Xihui Lin
Journal:  Int J Retina Vitreous       Date:  2022-04-05

6.  Pharmaceutical compounding of aflibercept in prefilled syringes does not affect structural integrity, stability or VEGF and Fc binding properties.

Authors:  Magne Sand Sivertsen; Øystein Kalsnes Jørstad; Algirdas Grevys; Stian Foss; Morten Carstens Moe; Jan Terje Andersen
Journal:  Sci Rep       Date:  2018-02-01       Impact factor: 4.379

7.  The use of prefilled adrenaline syringes improves cardiopulmonary resuscitation quality-high-fidelity simulator-based study.

Authors:  Radosław Zalewski; Mateusz Puślecki; Tomasz Kłosiewicz; Maciej Sip; Bartłomiej Perek
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

8.  A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes.

Authors:  Heidrun Elisabeth Lode; Torleif Tollefsrud Gjølberg; Stian Foss; Magne Sand Sivertsen; Jørgen Brustugun; Yvonne Andersson; Øystein Kalsnes Jørstad; Morten Carstens Moe; Jan Terje Andersen
Journal:  Sci Rep       Date:  2019-12-02       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.